Skip to main content
Enveric Biosciences, Inc. logo

Enveric Biosciences, Inc. — Investor Relations & Filings

Ticker · ENVB ISIN · US02362F3029 US Professional, scientific and technical activities
Open in API
Filings indexed 1,028 across all filing types
Latest filing 2023-09-01 Capital/Financing Update
Country US United States of America
Listing US ENVB

About Enveric Biosciences, Inc.

https://www.enveric.com/

Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of neuropsychiatric disorders. The company focuses on conditions such as anxiety, depression, and addiction. Leveraging its proprietary discovery and development platform, The Psybrary™, Enveric has created a robust intellectual property portfolio of novel molecules for specific mental health indications. Its development pipeline includes candidates such as EB-003 for difficult-to-treat mental health disorders and the EVM301 series.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2023
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an equity distribution agreement for common stock. It includes detailed information about the offering, sales agent, compensation, risk factors, and use of proceeds. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not a financial report, earnings release, or management discussion. It is clearly an update on the company's capital raising activities and financing terms. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, not just an announcement or a brief notice, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2023-09-01 English
Capital/Financing Update 2023
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 1, 2023, by Enveric Biosciences, Inc. It reports the entry into a material definitive agreement, specifically an Equity Distribution Agreement for an at-the-market offering of common stock. The document includes details about the agreement, the offering size, the sales agent, and the intended use of proceeds. It also references exhibits such as the agreement itself and legal opinions. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The content is focused on a capital raising transaction and related agreement disclosure. Therefore, this filing is best classified as a Capital/Financing Update (CAP).
2023-09-01 English
Investor Presentation 2023
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated August 28, 2023, by Enveric Biosciences, Inc. It primarily discloses the preparation and furnishing of an Investor Presentation for an upcoming investment conference. The text explicitly states that the presentation materials are furnished as Exhibit 99.1 and are intended for use in presentations to investors and other stakeholders. There are no financial statements or detailed financial data included in the text, only a description of the presentation and its intended use. The document is relatively short (4540 characters) and serves as a disclosure of the presentation's availability rather than the presentation itself. According to the classification rules, such a document is best classified as an Investor Presentation (IP) because it is about the presentation materials used for investor communication, not a report publication announcement or regulatory filing. Therefore, the filing type code is IP with high confidence.
2023-08-28 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce specific events or disclosures outside of regular periodic filings. The text includes a Regulation FD Disclosure about a patent issuance and a press release attached as an exhibit. There are no financial statements or detailed financial data presented, and the document is relatively short (4488 characters). It is primarily an announcement of an event and a press release, not a full financial report or earnings release. According to the rules, such a document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-08-28 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 21, 2023, by Enveric Biosciences, Inc. It reports a Regulation FD Disclosure about completing manufacturing of a drug material for a preclinical program. The document includes a press release as an exhibit and explicitly states that the information is furnished pursuant to Item 7.01 of Form 8-K. The content is a current report on a material event or corporate update, not a full financial report or earnings release. The document length is 4315 characters, which is relatively short and consistent with a current report rather than a comprehensive report. Form 8-K filings are generally classified as Regulatory Filings (RNS) unless they fit other specific categories, which this does not. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-08-21 English
Earnings Release 2023
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and references a press release announcing financial results for the second quarter ended June 30, 2023. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes a press release as an exhibit. The length is 3812 characters, which is relatively short and consistent with a current report filing rather than a full financial report. According to the rules, such a filing announcing financial results but primarily consisting of a press release is best classified as an Earnings Release (ER).
2023-08-14 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.